146 related articles for article (PubMed ID: 11162701)
21. Tumoural portal vein thrombosis. Enhancement with MnDPDP.
Marti-Bonmati L; Lonjedo E; Mathieu D; Coffin C; Poyatos C; Anglade MC
Acta Radiol; 1997 Jul; 38(4 Pt 2):655-9. PubMed ID: 9245960
[TBL] [Abstract][Full Text] [Related]
22. MnDPDP enhanced magnetic resonance imaging of focal liver lesions.
King LJ; Burkill GJ; Scurr ED; Vlavianos P; Murray-Lyons I; Healy JC
Clin Radiol; 2002 Dec; 57(12):1047-57. PubMed ID: 12475527
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities.
Ni Y; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):724-31. PubMed ID: 9245968
[TBL] [Abstract][Full Text] [Related]
24. MnDPDP as a negative hepatic contrast agent: evaluation of STIR imaging compared with T1-weighted SE and GE techniques.
Halavaara JT; Lamminen AE
J Comput Assist Tomogr; 1997; 21(1):94-9. PubMed ID: 9022776
[TBL] [Abstract][Full Text] [Related]
25. [Detection of liver metastases in colorectal cancer on chemotherapy. Comparative study between MRI with teslascan and computed tomography with intravenous contrast media].
Beziat C; Pilleul F; Yzebe D; Lombard-Bohas C; Mercier C; Valette PJ
J Radiol; 2004 Mar; 85(3):307-11. PubMed ID: 15192523
[TBL] [Abstract][Full Text] [Related]
26. Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging.
Ahlström H; Gehl HB
Acta Radiol; 1997 Jul; 38(4 Pt 2):660-4. PubMed ID: 9245961
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study.
Wang C; Ahlström H; Ekholm S; Fagertun H; Hellström M; Hemmingsson A; Holtås S; Isberg B; Jonnson E; Lönnemark-Magnusson M; McGill S; Wallengren NO; Westman L
Acta Radiol; 1997 Jul; 38(4 Pt 2):643-9. PubMed ID: 9245958
[TBL] [Abstract][Full Text] [Related]
28. MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings.
Kane PA; Ayton V; Walters HL; Benjamin I; Heaton ND; Williams R; Karani JB
Acta Radiol; 1997 Jul; 38(4 Pt 2):650-4. PubMed ID: 9245959
[TBL] [Abstract][Full Text] [Related]
29. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies.
Rummeny EJ; Torres CG; Kurdziel JC; Nilsen G; Op de Beeck B; Lundby B
Acta Radiol; 1997 Jul; 38(4 Pt 2):638-42. PubMed ID: 9245957
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety).
Federle MP; Chezmar JL; Rubin DL; Weinreb JC; Freeny PC; Semelka RC; Brown JJ; Borello JA; Lee JK; Mattrey R; Dachman AH; Saini S; Harmon B; Fenstermacher M; Pelsang RE; Harms SE; Mitchell DG; Halford HH; Anderson MW; Johnson CD; Francis IR; Bova JG; Kenney PJ; Klippenstein DL; Foster GS; Turner DA
J Magn Reson Imaging; 2000 Jul; 12(1):186-97. PubMed ID: 10931579
[TBL] [Abstract][Full Text] [Related]
32. Clinical and cost effectiveness of a new hepatocellular MRI contrast agent, mangafodipir trisodium, in the preoperative assessment of liver resectability.
Mann GN; Marx HF; Lai LL; Wagman LD
Ann Surg Oncol; 2001 Aug; 8(7):573-9. PubMed ID: 11508618
[TBL] [Abstract][Full Text] [Related]
33. Manganese dipyridoxyl diphosphate (MnDPDP)-enhanced magnetic resonance imaging of acute reperfused myocardial injury in a cat model: part II: comparison with cine magnetic resonance imaging.
Yang DH; Kim TH; Choi JW; Kim ST; Yoon JH; Shin JH; Seo JB; Lim TH
Invest Radiol; 2005 Jan; 40(1):56-61. PubMed ID: 15597021
[TBL] [Abstract][Full Text] [Related]
34. MnDPDP for MR imaging of the liver. Results from the European phase III studies.
Torres CG; Lundby B; Sterud AT; McGill S; Gordon PB; Bjerknes HS
Acta Radiol; 1997 Jul; 38(4 Pt 2):631-7. PubMed ID: 9245956
[TBL] [Abstract][Full Text] [Related]
35. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2.
Ni Y; Petré C; Bosmans H; Miao Y; Grant D; Baert AL; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):700-7. PubMed ID: 9245965
[TBL] [Abstract][Full Text] [Related]
36. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
37. Hepatobiliary MR imaging: first human experience with MnDPDP.
Lim KO; Stark DD; Leese PT; Pfefferbaum A; Rocklage SM; Quay SC
Radiology; 1991 Jan; 178(1):79-82. PubMed ID: 1898539
[TBL] [Abstract][Full Text] [Related]
38. Physicochemical characterisation of mangafodipir trisodium.
Tirkkonen B; Aukrust A; Couture E; Grace D; Haile Y; Holm KM; Hope H; Larsen A; Lunde HS; Sjøgren CE
Acta Radiol; 1997 Jul; 38(4 Pt 2):780-9. PubMed ID: 9245974
[TBL] [Abstract][Full Text] [Related]
39. NMR relaxation studies with MnDPDP.
Southon TE; Grant D; Bjørnerud A; Moen OM; Spilling B; Martinsen I; Refsum H
Acta Radiol; 1997 Jul; 38(4 Pt 2):708-16. PubMed ID: 9245966
[TBL] [Abstract][Full Text] [Related]
40. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results.
Sahani DV; O'Malley ME; Bhat S; Hahn PF; Saini S
J Comput Assist Tomogr; 2002; 26(2):216-22. PubMed ID: 11884777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
